{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:50:44Z","timestamp":1780469444282,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10388-024-01099-z","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T22:24:51Z","timestamp":1733696691000},"page":"272-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term efficacy of on-demand vonoprazan treatment for mild reflux esophagitis: success rates and predictors of treatment failure"],"prefix":"10.1007","volume":"22","author":[{"given":"Yoshimasa","family":"Hoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Koeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Rokugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Momma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kawami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-6104","authenticated-orcid":false,"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,8]]},"reference":[{"issue":"2","key":"1099_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","volume":"154","author":"JE Richter","year":"2018","unstructured":"Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):267\u201376.","journal-title":"Gastroenterology"},{"issue":"6","key":"1099_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","volume":"44","author":"Y Fujiwara","year":"2009","unstructured":"Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44(6):518\u201334.","journal-title":"J Gastroenterol"},{"issue":"4","key":"1099_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","volume":"162","author":"LE Targownik","year":"2022","unstructured":"Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334\u201342.","journal-title":"Gastroenterology"},{"issue":"9","key":"1099_CR4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.14309\/ajg.0000000000000731","volume":"115","author":"MF Vaezi","year":"2020","unstructured":"Vaezi MF, Pandolfino JE, Yadlapati RH, et al. ACG Clinical Guidelines: diagnosis and management of achalasia. Am J Gastroenterol. 2020;115(9):1393\u2013411.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1099_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240\u201351.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1099_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42(6):685\u201395.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1099_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000485795","volume":"97","author":"M Umezawa","year":"2018","unstructured":"Umezawa M, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for mild reflux esophagitis. Digestion. 2018;97(4):309\u201315.","journal-title":"Digestion"},{"issue":"1","key":"1099_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","volume":"111","author":"D Armstrong","year":"1996","unstructured":"Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology. 1996;111(1):85\u201392.","journal-title":"Gastroenterology"},{"issue":"9","key":"1099_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","volume":"39","author":"M Kusano","year":"2004","unstructured":"Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39(9):888\u201391.","journal-title":"J Gastroenterol"},{"issue":"1","key":"1099_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. Clinical Guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27\u201356.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1099_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5056\/jnm21095","volume":"28","author":"SJ Kang","year":"2022","unstructured":"Kang SJ, Jung HK, Tae CH, et al. On-demand versus continuous maintenance treatment of gastroesophageal reflux disease with proton pump inhibitors: a systematic review and meta-analysis. J Neurogastroenterol Motil. 2022;28(1):5\u201314.","journal-title":"J Neurogastroenterol Motil"},{"issue":"6","key":"1099_CR12","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","volume":"10","author":"JM Shin","year":"2008","unstructured":"Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528\u201334.","journal-title":"Curr Gastroenterol Rep"},{"issue":"2","key":"1099_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10388-018-00654-9","volume":"16","author":"Y Hoshikawa","year":"2019","unstructured":"Hoshikawa Y, Kawami N, Hoshino S, et al. Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus. 2019;16(2):201\u20136.","journal-title":"Esophagus"},{"issue":"10","key":"1099_CR14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/apt.17728","volume":"58","author":"R Fass","year":"2023","unstructured":"Fass R, Vaezi M, Sharma P, et al. Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Aliment Pharmacol Ther. 2023;58(10):1016\u201327.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1099_CR15","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.cgh.2007.08.011","volume":"5","author":"J Lee","year":"2007","unstructured":"Lee J, Anggiansah A, Anggiansah R, et al. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol. 2007;5(12):1392\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1099_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1365-2036.2010.04542.x","volume":"33","author":"A Becher","year":"2011","unstructured":"Becher A, Dent J. Systematic review: ageing and gastro-oesophageal reflux disease symptoms, oesophageal function and reflux oesophagitis. Aliment Pharmacol Ther. 2011;33(4):442\u201354.","journal-title":"Aliment Pharmacol Ther"},{"key":"1099_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.maturitas.2020.07.011","volume":"143","author":"E Kravvariti","year":"2021","unstructured":"Kravvariti E, Kotsani M, Mitsikostas DD, et al. Nocebo phenomena may be enhanced in aging: implications for clinical practice. Maturitas. 2021;143:10\u20136.","journal-title":"Maturitas"},{"issue":"7","key":"1099_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/gutjnl-2017-314722","volume":"67","author":"PC Gyawali","year":"2018","unstructured":"Gyawali PC, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: The Lyon consensus. Gut. 2018;67(7):1351\u201362.","journal-title":"Gut"},{"issue":"9","key":"1099_CR19","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1046\/j.1440-1746.2002.02783.x","volume":"17","author":"N Manabe","year":"2002","unstructured":"Manabe N, Yoshihara M, Sasaki A, et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol. 2002;17(9):949\u201354.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"1099_CR20","doi-asserted-by":"publisher","first-page":"794","DOI":"10.14309\/ajg.0000000000002173","volume":"118","author":"P Visaggi","year":"2023","unstructured":"Visaggi P, Del Corso G, Gyawali CP, et al. Ambulatory pH-impedance findings confirm that grade b esophagitis provides objective diagnosis of gastroesophageal reflux disease. Am J Gastroenterol. 2023;118(5):794\u2013801.","journal-title":"Am J Gastroenterol"},{"key":"1099_CR21","doi-asserted-by":"crossref","unstructured":"Gyawali PC, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2023;73(2):361\u2013371.","DOI":"10.1136\/gutjnl-2023-330616"},{"issue":"8","key":"1099_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-014-0164-8","volume":"32","author":"AJ Gawron","year":"2014","unstructured":"Gawron AJ, French DD, Pandolfino JE, et al. Economic evaluations of gastroesophageal reflux disease medical management. Pharmacoeconomics. 2014;32(8):745\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1099_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-022-14670-z","volume":"23","author":"N Li","year":"2023","unstructured":"Li N, Yang WL, Cai MH, et al. Burden of gastroesophageal reflux disease in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of disease study 2019. BMC Public Health. 2023;23(1):1\u201313.","journal-title":"BMC Public Health"},{"issue":"12","key":"1099_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00535-019-01609-2","volume":"54","author":"Y Yokoya","year":"2019","unstructured":"Yokoya Y, Igarashi A, Uda A, et al. Cost-utility analysis of a \u2018vonoprazan-first\u2019 strategy versus \u2018esomeprazole- or rabeprazole-first\u2019 strategy in GERD. J Gastroenterol. 2019;54(12):1083\u201395.","journal-title":"J Gastroenterol"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-024-01099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-024-01099-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-024-01099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:22:26Z","timestamp":1742732546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-024-01099-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1007\/s10388-024-01099-z","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,8]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katsuhiko Iwakiri received lecture fees from Takeda Pharmaceutical Company Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}